| Q61950032 | ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas |
| Q47448610 | Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions |
| Q36419325 | CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer |
| Q28385765 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk |
| Q36026731 | Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer |
| Q39408168 | Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence |
| Q35063160 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk |
| Q37002930 | Five endometrial cancer risk loci identified through genome-wide association analysis |
| Q37389405 | Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer |
| Q54940815 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. |
| Q47370686 | HER2 expression patterns in paired primary and metastatic endometrial cancer lesions |
| Q54440867 | High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. |
| Q43528769 | Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial |
| Q57170142 | Identification of nine new susceptibility loci for endometrial cancer |
| Q47879262 | In vivo MR spectroscopy predicts high tumor grade in endometrial cancer |
| Q46950736 | Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma |
| Q36333368 | Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. |
| Q27852608 | Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer |
| Q41878396 | Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers |
| Q48305261 | Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer |
| Q27852937 | Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer |
| Q33645463 | Switch in FOXA1 status associates with endometrial cancer progression |
| Q42317488 | Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer |